2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
August 4th 2022
Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.
June 13th 2022
Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.